Search results
NMDA receptor antagonists are a class of drugs that work to antagonize, or inhibit the action of, the N -Methyl- D -aspartate receptor ( NMDAR ). They are commonly used as anesthetics for humans and non-human animals; the state of anesthesia they induce is referred to as dissociative anesthesia.
NMDA antagonists are drugs that block the action of glutamate on NMDA receptors in the brain. They may treat Alzheimer's disease, pseudobulbar affect, and depression, but can cause dizziness, confusion, and other side effects.
Dec 11, 2022 · Introduction. The N-methyl-D-aspartate (NMDA) receptor is a receptor of glutamate, the primary excitatory neurotransmitter in the human brain. It plays an integral role in synaptic plasticity, which is a neuronal mechanism believed to be the basis of memory formation.
- Benjamin E. Jewett, Bicky Thapa
- 2022/12/11
- 2018
Jan 31, 2024 · Memantine is an antagonist of the N -methyl-D-aspartate receptor (NMDAR) subtype of glutamate receptor. Memantine is used to slow the neurotoxicity involved in Alzheimer disease and other neurodegenerative diseases. [1] . Glutamate is a major excitatory neurotransmitter in the brain.
- Brianne Kuns, Alan Rosani, Dona Varghese
- 2022/07/11
Sep 2, 2022 · Learn how NMDA receptor antagonists work in the brain and how they may help slow down Alzheimer's disease. Find out about memantine, a drug that blocks NMDA receptors, and other similar drugs that have been studied for various conditions.
Apr 12, 2024 · This review explores the molecular mechanisms of NMDA receptor antagonists, emphasizing their structure, function, types, challenges, and future prospects in treating NDs. Despite extensive research on competitive and noncompetitive NMDA receptor antagonists, the quest for effective treatments still faces significant hurdles.
The development of NMDA receptor antagonists for treatment of depression is chronicled, from initial studies up through the recent FDA approval of intranasal esketamine as well as other newer compounds that have shown recent promise in clinical trials.
